The study looked at the effectiveness of Jardiance (empagliflozin), which is used to lower blood sugar levels in adults with type 2 diabetes.
A total of 7,000 people took part in the EMPA-REG OUTCOME study.
Findings showed that Jardiance cut the risk for on-set or worsening kidney disease by 39 per cent, compared with those who had been taking placebo or standard type 2 diabetes treatment and had a history of heart disease.
The results also showed a 55 per cent reduction in renal replacement therapy.
Speaking at the annual conference of the American Diabetes Association, Dr Christoph Wanner, from the department of medicine, division of nephrology at Würzburg University Clinic, Würzburg, said: “Kidney disease is developed in approximately 35 per cent of the population with type 2 diabetes.
“In the last 15 years, we have had no new diabetes-specific kidney treatment until today.”
Lead investigator Dr Bernard Zinman, director of the Diabetes Centre at Mount Sinai Hospital and senior scientist at the Lunenfeld Tanenbaum Research Institute, added: “As people with type 2 diabetes age, their risk for cardiovascular events increases.
“These sub-analyses suggest that empagliflozin is associated with reducing cardiovascular events regardless of age when starting treatment.”
The results were also published in The New England Journal of Medicine.